Market Intelligence, Clinical Progress, and High-Purity Reagents for Splicing Modulator Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DHX8 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DHX8 Full-Length / Helicase Domain Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. ATP-binding competent. | View DHX8 Products |
| Gene Delivery | DHX8 Promise-ORF / Lentivirus. Full-length ORF with N-terminal FLAG tag for stable cell lines. CMV promoter. | View DHX8 Products |
| Benchmark Ab | Anti-DHX8 Recombinant Rabbit mAb (Clone DHX8-001). Validated for Western, IP, ChIP/ICC. | View DHX8 Products |
| Validator | DHX8 siRNA Set (3 unique targets). For knockdown verification in splicing reporter assays. | View DHX8 Products |
| Paralog Control | DHX9 Helicase Domain. Selectivity counter-screening against DEAH-box paralog. Sequence Verified. | View DHX9 Products |
| Related Target A | DHX15. DEAH-box paralog; critical for selectivity counter-screening. | View DHX15 Products |
| Related Target B | SF3B1 (WT and mutant proteins E622K, R625H). Core spliceosome component; synthetic lethality & pathway synergy. | View SF3B1 Products |
| Related Target C | PRPF8. Major spliceosomal scaffolding protein; critical for splicing fidelity. | View PRPF8 Products |
| Related Target D | PRMT5. Synthetic lethal partner in spliceosomal-mutant cancers. | View PRMT5 Products |
Critical Assay Challenges and TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Assay Baseline Stability | High Purity (>95%) recombinant DHX8 with preserved ATP-dependent helicase structural domains. |
| Helicase Activity (ATP-dependent unwinding) | Full-length DHX8 with intact RecA1/RecA2 domains; ATPase competent; Sequence Verified by Mass Spec. |
| Paralog Selectivity (DHX9/DHX15 off-target) | DEAH-box family panel (DHX8, DHX9, DHX15) with >95% purity for cross-reactivity screening. |
| Spliceosome Complex Interactions | Sequence Verified wild-type proteins and SF3B1/PRPF8 panels for co-IP studies. |
| Cell-Based Splicing Validation | Lentivirus particles with puromycin selection; pre-titered for stable integration in reporter cell lines. |
| Compound Binding Verification | Active site mutant (E196A) available as negative control for binding specificity confirmation. |
| Drug Resistance Prediction | Key mutant proteins (e.g., catalytic site variants) for resistance profiling. |
| Intracellular Target Engagement | Cell-based assay support via stable cell line generation. |
Live DHX8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
DHX8 (DEAH-box helicase 8) is a critical enzyme catalyzing the release of mature mRNA from the spliceosome during the second step of pre-mRNA splicing. It contains a conserved S1 motif, an ATP-binding helicase domain, and a helicase C-terminal domain. Clinically, a missense variant (VAR_083620) has been identified in a patient with a neurodevelopmental disorder, and a common polymorphism (rs34285079) is documented in dbSNP, though their functional significance remains uncertain.
The race for RNA splicing therapeutics is intensifying, with early-stage discovery shifting from broad cytotoxic agents to targeted spliceosome modulators. DHX8 has gained attention for synthetic lethal vulnerabilities in splicing factor mutant cancers (particularly SF3B1-mutant myeloid malignancies) and as a host factor for viral RNA processing (e.g., flaviviruses, HIV). Current R&D focuses on ATP-competitive small molecules and allosteric inhibitors, with increasing emphasis on selectivity against DEAH-box paralogs (DHX9, DHX15, DHX16). The field is transitioning from target validation to lead optimization, and the next wave will likely include PROTAC-mediated degradation and rational combination strategies exploiting synthetic lethality.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic consortia, Emerging biotech | Solid Tumors (CRC, Gastric, SF3B1 mut), MDS/AML | ATPase/Helicase Assays (Need full-length active protein); Selectivity Panel (DHX9/DHX15) |
| PROTACs / Molecular Glues | Undisclosed biotech, Early translational programs | Refractory Cancers, Hematologic Malignancies | Binary/Ternary Complex Formation (Need purified DHX8 and mutant binding controls) |
| Antivirals (Host-directed) | NIH-funded programs | Flaviviruses, HIV | Viral RNA unwinding assay (Need high-purity helicase domain) |
| Genetic Modulation (siRNA / RNAi / Gene Therapy) | Academic/Translational labs, Gene therapy platforms | Oncology, Spliceosomopathies | Knockdown Validation (Need validated siRNA and Lentivirus systems) |
| Synthetic Lethal Combinations | Pharma Consortia | Spliceosomal-Mutant Cancers | Cell-based Splicing Reporter (Need stable cell lines via Lentivirus) |